Ausgabe 1/2008
Inhalt (13 Artikel)
INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin
Kathryn A. Mason, David Valdecanas, Nancy R. Hunter, Luka Milas
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits
Vinay Bhaskar, Melvin Fox, Danna Breinberg, Melanie H-L Wong, Pauline E. Wales, Susan Rhodes, Robert B. DuBridge, Vanitha Ramakrishnan
Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis
Arkadiusz Z. Dudek, Pawel Zwolak, Piotr Jasinski, Kaoru Terai, Nathan J. Gallus, Marna E. Ericson, Faris Farassati
Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity
Praveen Rajendran, Manu Jaggi, Manoj K. Singh, Rama Mukherjee, Anand C. Burman
Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
Catherine Delbaldo, Eric Raymond, Karina Vera, Luz Hammershaimb, Karen Kaucic, Stéphanie Lozahic, Michel Marty, Sandrine Faivre
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
Kyle Holen, Leonard B. Saltz, Ellen Hollywood, Konrad Burk, Axel-Rainer Hanauske
Prognostic factors among cancer patients with good performance status screened for phase I trials
Nicolas Penel, Marie Vanseymortier, Marie-Edith Bonneterre, Stéphanie Clisant, Eric Dansin, Yvette Vendel, Régis Beuscart, Jacques Bonneterre
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
Elisabeth I. Heath, Keith Bible, Robert E. Martell, Daniel C. Adelman, Patricia M. LoRusso
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study
Emilio Esteban, Noemi Villanueva, Isabel Muñiz, Yolanda Fernández, Joaquin Fra, Maria Luque, Paula Jiménez, Beatriz Llorente, Marta Capelan, José M. Vieitez, Enrique Estrada, José M. Buesa, Angel Jiménez-Lacave
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
Joseph G. Kattan, Fady S. Farhat, Georges Y. Chahine, Fady L. Nasr, Walid T. Moukadem, Fariha C. Younes, Nadine J. Yazbeck, Marwan G. Ghosn
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R. Blumenschein Jr., Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Charles Lu, Ashok J. Kumar, Justin L. Ricker, Judy H. Chiao, Cong Chen, Stanley R. Frankel
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma
Karl D. Lewis, William A. Robinson, Michael J. Millward, Alex Powell, Timothy J. Price, Damien B. Thomson, Euan T. Walpole, Andrew M. Haydon, Brian R. Creese, Kaye L. Roberts, John R. Zalcberg, Rene Gonzalez
Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity
Timothy R. Asmis, Ki Y. Chung, Jerrold B. Teitcher, David P. Kelsen, Manish A. Shah